Program

In-person AND virtual! – We are pioneering a new conference format that will connect in-person and virtual audiences to create a unique experience. Matching the innovation that comes through our members’ work, ISPOR is pushing the boundaries of innovation to design an event that works in today’s quickly changing environment. 

In-person registration included the full virtual experience, and virtual-only attendees will be able to tune into live in-person sessions and/or watch captured in-person sessions on-demand in addition to having a variety of virtual-only sessions to attend.

Can Pharmaceutical Pricing Move Beyond Cost/QALY for Value Consideration?

Speaker(s)

Moderator: Omar Dabbous, MD, MPH, Novartis Gene Therapies, Inc., Bannockburn, IL, USA
Speakers: Michael Drummond, MCom, DPhil, Centre for Health Economics, University of York, York, UK; Sean D Sullivan, BScPharm, PhD, University of Washington, Seattle, WA, USA

Current economic evaluation studies may underestimate the value of innovative cell and gene therapies in rare diseases, impacting on Health Technology Assessment (HTA) frameworks, market access and pricing decisions. This symposium will explore additional add-on benefits of gene therapies apart from quality-adjusted life years (QALYs) that may be considered, how these can be quantified, and their role in influencing economic modelling. Using case studies of value assessment frameworks, panelists will discuss the value of pricing factors beyond cost and QALY considerations for gene therapies.

Code

211

Topic

Economic Evaluation